SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 274-283

  Moss, Adrian C ^a,b,c   Jacobson, Gregory M ^a   Walker, Lauren E ^a   Blake, Neil W ^b   Marshall, Ernie ^c   Coulson, Judy M ^a,b  

^a MRC Centre for Drug Safety Science   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; ETOPOSIDE; GEMCITABINE; MESSENGER RNA; PCSK1 PROTEIN; PLATINUM DERIVATIVE; RE 1 SILENCING TRANSCRIPTION FACTOR; RNA; SECRETOGRANIN 3; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; VGF PROTEIN;

ADULT; AGED; ARTICLE; BLOOD; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYBRIDIZATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFICIENCY; PROTEIN DEPLETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHROMOGRANINS; DNA FINGERPRINTING; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; RNA, MESSENGER; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 58849115512     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1163     Document Type: Article

References (48)

1. Coulson JM, Ocejo-Garcia M, Woll PJ. Neuroendocrine phenotype of small cell lung cancer. Methods Mol Med 2003;74:61-73.
2. Tallett A, Chilvers ER, Hannah S, et al. Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells. Cancer Res 1996;56: 4255-63.
3. Ciombor KK, Rocha Lima CM. Management of small cell lung cancer. Curr Treat Options Oncol 2006;7:59-68.
4. Carney ON, Marangos RJ, Ihde DC, et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982:1:583-5.
5. Lamy P, Grenier J, Kramar A, Pujol JL. Pro-gastrin-re- leasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000;29:197-203.
6. Hansen M, Hammer M, Hummer L. ACTH, ADH, and calcitonin concentrations as markers of response and relapse in small-cell carcinoma of the lung. Cancer 1980;46:2062-7.
7. Degorce F, Goumon Y, Jacquemart L, et al. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 1999;79:65-71.
8. Begueret H, Vergier B, Begueret J, et al. Detection of circulating cells expressing chromogranin A gene transcripts in patients with lung neuroendocrine carcinoma. Eur J Cancer 2002;38:2325-30.
9. SaitoT, Kobayashi M, Harada R, Uemura Y, Taguchi H. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA. Cancer 2003;97:2504-11.
10. Lacroix J, Becker HD, Woerner SM, Rittgen W, Drings P, von Knebel Doeberitz M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP- specific RT-PCR. Int J Cancer 2001;92:1 -8.
11. Bessho A, Tabata M, Kiura K, et al. Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by reverse transcriptase-polymerase chain reaction. Anticancer Res 2000;20: 1149-54.
12. Chong JA, Tapia-Ramirez J, Kim S, et al. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995;80: 949-57.
13. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 1995;267: 1360-3.
14. Coulson JM. Transcriptional regulation: cancer, neurons and the REST. Curr Biol 2005;15:R665-8.
15. Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle 2006;5:1929-35.
16. Coulson JM, Edgson JL, Woll PJ, Quinn JP. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res 2000;60:1840-4.
17. Gurrola-Diaz C, Lacroix J, Dihlmann S, Becker CM, von Knebel Doeberitz M. Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor α1 subunit in small-cell lung cancer cells. Oncogene 2003;22:5636-45.
18. Neumann SB, Seitz R, Gorzella A, Heister A, Doeberitz MK, Becker CM. Relaxation of glycine receptor and onconeural gene transcription control in NRSF deficient small cell lung cancer cell lines. Brain Res Mol Brain Res 2004;120:173-81.
19. Spencer EM, Chandler KE, Haddley K, et al. Regulation and role of RESTand REST4 variants in modulation of gene expression in in vivo and in vitro in epilepsy models. Neurobiol Dis 2006;24:41 -52.
20. 20. Watanabe H, Mizutani T, Haraguchi T, et al. SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 2006;25:470-9.
21. Coulson JM, Fiskerstrand CE, Woll PJ, Quinn JR. Arginine vasopressin promoter regulation is mediated by a neuron-restrictive silencer element in small cell lung cancer. Cancer Res 1999;59:5123-7.
22. Ocejo-Garcia M, Ahmed SI, Coulson JM, Woll PJ. Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. Lung Cancer 2001;33:1-9.
23. Chute JP, Taylor E, Williams J, Kaye F, Venzon D, Johnson BE. A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res 2006;12:888-96.
24. Coulson JM, Ahmed SI, Quinn JP, Woll PJ. Detection of small cell lung cancer by RT-PCR for neuropeptides, neuropeptide receptors, or a splice variant of the neuron restrictive silencer factor. Methods Mol Med 2003;75:335-52.
25. Otto SJ, McCorkle SR, Hover J, et al. A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions. J Neurosci 2007;27:6729-39.
26. Johnson DS, Mortazavi A, Myers RM, Wold B. Genome-wide mapping of in vivo protein-DNA interactions. Science 2007;316:1497-502.
27. North WG, Du JL. Key peptide processing enzymes are expressed by a variant form of small-cell carcinoma of the lung. Peptides 1998;19:1743-7.
28. Benatar M, Blaes F, Johnston I, et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol 2001;113:153-62.
29. Patel PD, Bochar DA, Turner DL, Meng F, Mueller HM, Pontrello CG. Regulation of tryptophan hydroxy lase-2 gene expression by a bipartite RE-1 silencer of transcription/neuron restrictive silencing factor (REST/NRSF) binding motif. J Biol Chem 2007;282: 26717-24.
30. Zhang C, Xuan Z, Otto S, et al. A clustering property of highly-degenerate transcription factor binding sites in the mammalian genome. Nucleic Acids Res 2006; 34:2238-46.
31. Wu J, Xie X. Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biol 2006;7:R85.
32. Pance A, Livesey FJ, Jackson AP. A role for the transcriptional repressor REST in maintaining the phenotype of neurosecretory-deficient PC12 cells. J Neurochem 2006;99:1435-44.
33. Mortazavi A, Thompson EC, Garcia ST, Myers RM, Wold B. Comparative genomics modeling of the NRSF/RESTrepressor network: from single conserved sites to genome-wide repertoire. Genome Res 2006; 16:1208-21.
34. Johnson R, Gamblin RJ, Ooi L, et al. Identification of the REST regulon reveals extensive transposable element-mediated binding site duplication. Nucleic Acids Res 2006;34:3862-77.
35. Bruce AW, Krejci A, Ooi L, et al. The transcriptional repressor REST is a critical regulator of the neurosecretory phenotype. J Neurochem 2006;98:1828-40.
36. Bruce AW, Donaldson IJ, Wood IC, et al. Genomewide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc Natl Acad Sci U S A 2004;101:10458-63.
37. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006;147:126-32.
38. Kowalewska M, Chechlinska M, Markowicz S, Kober P, Nowak R. The relevance of RT- PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur J Cancer 2006;42:2671 -4.
39. WestbrookTF, Martin ES, Schlabach MR, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005;121:837-48.
40. Sorhaug S, Steinshamn S, Haaverstad R, Nordrum IS, Martinsen TC, Waldum HL. Expression of neuroendocrine markers in non-small cell lung cancer. APMIS 2007;115:152-63.
41. Ab' Saber AM, Massoni Neto LM, Bianchi CP, et al. Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas. Ann Thorac Surg 2004;77:1883-90.
42. Jungraithmayr W, Kayser G, Passlick B, Eggeling S. Neuroendocrine differentiation and neuroendocrine morphology as two different patterns in large-cell bronchial carcinomas: outcome after complete resection. World J Surg Oncol 2006;4:61.
43. Hosaka M, Suda M, Sakai Y, Izumi T, Watanabe T, Takeuchi T. Secretogranin III binds to cholesterol in the secretory granule membrane as an adapter for chromogranin A. J Biol Chem 2004;279: 3627-34.
44. Hosaka M, Watanabe T, Sakai Y, Kato T, Takeuchi T. Interaction between secretogranin III and carboxy- peptidase E facilitates prohormone sorting within secretory granules. J Cell Sci 2005;118:4785-95.
45. Hosaka M, Watanabe T, Sakai Y, Uchiyama Y, Takeuchi T. Identification of a chromogranin A domain that mediates binding to secretogranin III and targeting to secretory granules in pituitary cells and pancreatic β-cells. Mol Biol Cell 2002;13:3388-99.
46. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004;35:255-62.
47. Peters D, Freund J, Ochs RL. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol CancerTher 2005;4:1605-16.
48. Watson MB, Lind MJ, Smith L, Drew PJ, Cawkwell L. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model. Acta Oncol 2007;46:651 -8.